|±¾ÆÚĿ¼/Table of Contents|

[1]Ð쳩,ÕÅÀû¶«.È®Äò°±Ëá´úлͨ·ÔÚÒÖÓôÖ¢ÖеÄÑо¿½øÕ¹[J].ҽѧÑо¿ÓëÕ½´´É˾ÈÖÎ(ԭҽѧÑо¿Éúѧ±¨),2022,24(1):69-72.[doi:10.3969/j.issn.1672-271X.2022.01.015]
¡¡XU Chang,ZHANG Li-dong.Research advances of kynurenine pathway in depressive disorder[J].JOURNAL OF MEDICALRESEARCH ¡ªCOMBAT TRAUMA CARE,2022,24(1):69-72.[doi:10.3969/j.issn.1672-271X.2022.01.015]
µã»÷¸´ÖÆ

È®Äò°±Ëá´úлͨ·ÔÚÒÖÓôÖ¢ÖеÄÑо¿½øÕ¹()

¡¶Ò½Ñ§Ñо¿ÓëÕ½´´É˾ÈÖΡ·£¨Ô­Ò½Ñ§Ñо¿Éúѧ±¨£©[ISSN:1672-271X/CN:32-1713/R]

¾í:
µÚ24¾í
ÆÚÊý:
2022Äê1ÆÚ
Ò³Âë:
69-72
À¸Ä¿:
×ÛÊö
³ö°æÈÕÆÚ:
2022-02-20

ÎÄÕÂÐÅÏ¢/Info

Title:
Research advances of kynurenine pathway in depressive disorder
×÷Õß:
Ð쳩ÕÅÀû¶«
×÷Õßµ¥Î»£º210002ÄϾ©£¬ÄϾ©´óѧҽѧԺ¸½Êô½ðÁêÒ½Ôº£¨¶«²¿Õ½Çø×ÜÒ½Ôº£©Âé×í¿Æ£¨Ð쳩¡¢ÕÅÀû¶«£©
Author(s):
XU Chang ZHANG Li-dong
(Department of Anesthesiology, Jinling Hospital, Medical School of Nanjing University/General Hospital of Eastern Theater Command£¬PLA£¬Nanjing 210002£¬Jiangsu£¬China)
¹Ø¼ü´Ê:
È®Äò°±ËáÈ®Äò°±Ëá´úлͨ·ÒÖÓôÖ¢à­ßøËáÈ®ÄòÏ©Ëá
Keywords:
kynurenine kynurenine pathway depression quinolinic acidkynurenine acid
·ÖÀàºÅ:
R749
DOI:
10.3969/j.issn.1672-271X.2022.01.015
ÎÄÏ×±êÖ¾Âë:
A
ÕªÒª:
È®Äò°±Ëá´úлͨ·£¨KP£©ÊÇÉ«°±Ëá´úлµÄÖ÷Ҫ;¾¶¡£Ô½À´Ô½¶àµÄÑо¿±íÃ÷£¬É«°±Ëá¾­KP´úл²úÉúµÄһϵÁлîÐÔÎïÖÊÓëÒÖÓôÖ¢µÄ·¢Éú¡¢·¢Õ¹ÃÜÇÐÏà¹Ø¡£ÓÐÑо¿±íʾ£¬ÒÖÓôÖ¢»¼ÕßÑ×Ö¢Òò×ÓˮƽµÄÉý¸ßÓëKP´úлÃÜÇÐÏà¹Ø£¬Èçµ¼ÖÂÉñ¾­¶¾ÐÔ²úÎïQUINÔö¸ß¡¢±£»¤²úÎïKYNA½µµÍ¡£ÎÄÕÂÖ÷Òª¶ÔKP¡¢´úл²úÎï¼°Æä²ÎÓëÒÖÓôÖ¢µÄ·¢²¡ÓëÖÎÁƵÈÏà¹ØÎÊÌâ½øÐÐ×ÛÊö¡£
Abstract:
The kynurenine pathway is a major route of tryptophan metabolism. Emerging evidence suggests that a series of kynurenine metabolites are involved in the occurrence and development of depression. Studies have shown that increased levels of inflammatory factors in patients with depression are closely related to kynurenine metabolites, such as increased levels of neurotoxic product quinolinic acid and decreased levels of neuroprotective product kynurenine acid. This review focuses onthe metabolic pathway, metabolites and relevant issues in the pathogenesis and treatment of depression, aiming to provide new targets and predictive methods for the treatment of depression.

²Î¿¼ÎÄÏ×/References:

[1]ºúº£á°.Çé¸ÐÓëÉç»áÐÐΪµÄÉñ¾­»úÖÆÑо¿½øÕ¹[J].Öйú¿Æѧ:ÉúÃü¿Æѧ,2021,51(2):105-115.
[2]Quintana DS, Steen NE, Andreassen OA. The Promise of Intranasal Esketamine as a Novel and Effective Antidepressant[J]. JAMA Psychiatry, 2018, 75(2):123-124.
[3]Tao X, Yan M, Wang L, et al. Homeostasis Imbalance of Microglia and Astrocytes Leads to Alteration in the Metabolites of the Kynurenine Pathway in LPS-Induced Depressive-LikeMice[J]. Int J Mol Sci, 2020, 21(4):1460.
[4]Kennedy PJ, Cryan JF, Dinan TG, et al. Kynurenine pathway metabolism and the microbiota-gut-brain axis[J]. Neuropharmacology, 2017, 112(Pt B):399-412.
[5]ÍõÀöɯ,ÁõÐÂÃñ,·ëÀû,µÈ.È®Äò°±Ëáͨ·ÔÚÉñ¾­ÍËÐÐÐÔ¼²²¡ÖеÄÑо¿½øÕ¹[J].Öйú±È½ÏҽѧÔÓÖ¾,2015,25(11):69-75.
[6]Muneer A. Kynurenine Pathway of Tryptophan Metabolism in Neuropsychiatric Disorders: Pathophysiologic and TherapeuticConsiderations[J]. Clin Psychopharmacol Neurosci, 2020, 18(4):507-526.
[7]¦Zzt¨¹rk M, Yal¢cn Sapmaz ÿðþ ‰C , Kandemir H, et al. The role of the kynurenine pathway and quinolinic acid in adolescent major depressive disorder[J]. Int J Clin Pract, 2021,75(4):e13739.
[8]Heisler JM, O¡¯Connor JC. Indoleamine 2,3-dioxygenase-dependent neurotoxic kynurenine metabolism mediates inflammation-induced deficit in recognition memory[J]. Brain Behav Immun, 2015, 50:115-124.
[9]Ogyu K, Kubo K, Noda Y, et al. Kynurenine pathway in depression: A systematic review and meta-analysis[J]. Neurosci Biobehav Rev, 2018, 90:16-25.
[10]Kim YK, Jeon SW. Neuroinflammation and the Immune-Kynurenine Pathway in AnxietyDisorders[J]. Curr Neuropharmacol, 2018, 16(5):574-582.
[11]O¡¯Farrell K, Fagan E, Connor TJ, et al. Inhibition of the kynurenine pathway protects against reactive microglial-associated reductions in the complexity of primary corticalneurons[J]. Eur J Pharmacol, 2017, 810:163-173.
[12]da Silveira TL, Zamberlan DC, Arantes LP, et al. Quinolinic acid and glutamatergic neurodegeneration in Caenorhabditis elegans[J]. Neurotoxicology, 2018, 67:94-101.
[13]Baranyi A, Meinitzer A, Breitenecker RJ, et al. Quinolinic Acid Responses during Interferon-alpha-Induced Depressive Symptomatology in Patients with Chronic Hepatitis C Infection - A Novel Aspect for Depression and Inflammatory Hypothesis[J]. PLoS One, 2015, 10(9):e0137022.
[14]Erhardt S, Lim CK, Linderholm KR, et al. Connecting inflammation with glutamate agonism insuicidality[J]. Neuropsychopharmacology, 2013, 38(5):743-752.
[15]Bartoli F, Misiak B, Callovini T, et al. The kynurenine pathway in bipolar disorder: a meta-analysis on the peripheral blood levels of tryptophan and relatedmetabolites[J]. Mol Psychiatry, 26,7 (2021): 3419-3429.
[16]Wiedlocha M, Marcinowicz P, Krupa R, et al. Effect of antidepressant treatment on peripheral inflammation markers - A meta-analysis[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2018, 80(Pt C):217-226.
[17]Savitz J, Drevets WC, Wurfel BE, et al. Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressivedisorder[J]. Brain Behav Immun, 2015, 46:55-59.
[18]Bay-Richter C, Linderholm KR, Lim CK, et al. A role for inflammatory metabolites as modulators of the glutamate N-methyl-D-aspartate receptor in depression and suicidality[J]. Brain Behav Immun, 2015, 43:110-117.
[19]Birner A, Platzer M, Bengesser SA, et al. Increased breakdown of kynurenine towards its neurotoxic branch in bipolardisorder[J]. PLoS One, 2017, 12(2):e0172699.
[20]Brundin L, Sellgren CM, Lim CK, et al. An enzyme in the kynurenine pathway that governs vulnerability to suicidal behavior by regulating excitotoxicity andneuroinflammation[J]. Transl Psychiatry, 2016, 6(8):e865.
[21]Liu X-C, Erhardt S, Goiny M, et al. Decreased levels of kynurenic acid in prefrontal cortex in a genetic animal model ofdepression[J]. Acta Neuropsychiatr, 2017, 29(1):54-58.
[22]Laumet G, Zhou W, Dantzer R, et al. Upregulation of neuronal kynurenine 3-monooxygenase mediates depression-like behavior in a mouse model of neuropathicpain[J]. Brain Behav Immun, 2017, 66:94-102.
[23]Zhang K, Liu R, Gao Y, et al. Electroacupuncture Relieves LPS-Induced Depression-Like Behaviour in Rats Through IDO-Mediated Tryptophan-DegradingPathway[J]. Neuropsychiatr Dis Treat, 2020, 16:2257-2266.
[24]Fischer CW, Eskelund A, Budac DP, et al. Interferon-alpha treatment induces depression-like behaviour accompanied by elevated hippocampal quinolinic acid levels in rats[J]. Behav Brain Res, 2015, 293:166-172.
[25]Souza LC, Jesse CR, de Gomes MG, et al. Activation of Brain Indoleamine-2,3-dioxygenase Contributes to Depressive-Like Behavior Induced by an Intracerebroventricular Injection of Streptozotocin in Mice[J]. Neurochem Res, 2017, 42(10):2982-2995.
[26]Fertan E, Stover KRJ, Brant MG, et al. Effects of the Novel IDO Inhibitor DWG-1036 on the Behavior of Male and Female 3xTg-ADMice[J]. Front Pharmacol, 2019, 10:1044.
[27]Bano S, Gitay M, Ara I, et al. Acute effects of serotonergic antidepressants on tryptophan metabolism and corticosterone levels inrats[J]. Pak J Pharm Sci, 2010, 23(3):266-272.
[28]Zhou Y, Zheng W, Liu W, et al. Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression[J]. Brain Behav Immun, 2018, 74:205-212.

ÏàËÆÎÄÏ×/References:

±¸×¢/Memo

±¸×¢/Memo:
-
¸üÐÂÈÕÆÚ/Last Update: 2022-02-21